Bioinformatic Analysis for Potential Biomarkers and Therapeutic Targets of T2DM-related MI

References

• Pillon NJ, Loos RJF, Marshall SM, Zierath JR. Metabolic consequences of obesity and type 2 diabetes: balancing genes and environment for personalized care. Cell. 2021;184(6):1530–1544.
   PubMed Web of Science ®Google Scholar
• Magliano DJ, Chen L, Islam RM, et al. Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings. Lancet Diabetes Endocrinol. 2021;9(4):203–211.
   PubMed Web of Science ®Google Scholar
• Mekhaimar M, Dargham S, El-Shazly M, Al Suwaidi J, Jneid H, Abi Khalil C. Diabetes-related cardiovascular and economic burden in patients hospitalized for heart failure in the US: a recent temporal trend analysis from the National Inpatient Sample. Heart Fail Rev. 2021;26(2):289–300.
   PubMed Web of Science ®Google Scholar
• Perveen S, Shahbaz M, Ansari MS, Keshavjee K, Guergachi A. A hybrid approach for modeling Type 2 diabetes mellitus progression. Front Genet. 2019;10:1076.
   PubMed Web of Science ®Google Scholar
• Huang JX, Liao YF, Li YM. Clinical features and microvascular complications risk factors of early-onset Type 2 diabetes mellitus. Curr Med Sci. 2019;39(5):754–758.
   PubMed Web of Science ®Google Scholar
• Davidson JA. SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence. Postgrad Med. 2019;131(4):251–260.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Ding X, Hua B, et al. Predictive effect of triglycerideglucose index on clinical events in patients with type 2 diabetes mellitus and acute myocardial infarction: results from an observational cohort study in China. Cardiovasc Diabetol. 2021;20(1):43.
   PubMed Web of Science ®Google Scholar
• Tajik AA, Dobre D, Aguilar D, et al. A history of diabetes predicts outcomes following myocardial infarction: an analysis of the 28 771 patients in the high-risk MI database. Eur J Heart Fail. 2017;19(5):635–642.
   PubMed Web of Science ®Google Scholar
• Murcia AM, Hennekens CH, Lamas GA, et al. Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med. 2004;164(20):2273–2279.
   PubMedGoogle Scholar
• Potier L, Roussel R, Zeller M, et al. Chronic kidney disease, diabetes, and risk of mortality after acute myocardial infarction: insight from the FAST-MI program. Diabetes Care. 2020;43(3):e43–e44.
   PubMed Web of Science ®Google Scholar
• Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol. 2014;171(8):2080–2090.
   PubMed Web of Science ®Google Scholar
• Schilling JD. The mitochondria in diabetic heart failure: from pathogenesis to therapeutic promise. Antioxid Redox Signal. 2015;22(17):1515–1526.
   PubMed Web of Science ®Google Scholar
• Cui J, Liu Y, Li Y, Xu F, Liu Y. Type 2 diabetes and myocardial infarction: recent clinical evidence and perspective. Front Cardiovasc Med. 2021;8:644189.
   PubMed Web of Science ®Google Scholar
• Dahl-Jorgensen K, Larsen JR, Hanssen KF. Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment? Diabetologia. 2005;48(8):1445–1453.
   PubMed Web of Science ®Google Scholar
• Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation. Int J Mol Sci. 2020;21:5.
   Web of Science ®Google Scholar
• Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88–98.
   PubMed Web of Science ®Google Scholar
• Lee YB, Han K, Kim B, et al. Risk of early mortality and cardiovascular disease according to the presence of recently-diagnosed diabetes and requirement for insulin treatment: a nationwide study. J Diabetes Investig. 2021. doi:10.1111/jdi.13539
   Web of Science ®Google Scholar
• Lejay A, Fang F, John R, et al. Ischemia reperfusion injury, ischemic conditioning and diabetes mellitus. J Mol Cell Cardiol. 2016;91:11–22.
   PubMed Web of Science ®Google Scholar
• Loria V, Dato I, Graziani F, Biasucci LM. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm. 2008;2008:135625.
   PubMed Web of Science ®Google Scholar
• Ikitimur B, Karadag B. Role of myeloperoxidase in cardiology. Future Cardiol. 2010;6(5):693–702.
   PubMedGoogle Scholar
• Teng N, Maghzal GJ, Talib J, Rashid I, Lau AK, Stocker R. The roles of myeloperoxidase in coronary artery disease and its potential implication in plaque rupture. Redox Rep. 2017;22(2):51–73.
   PubMed Web of Science ®Google Scholar
• Kolodziej AR, Abo-Aly M, Elsawalhy E, Campbell C, Ziada KM, Abdel-Latif A. Prognostic role of elevated myeloperoxidase in patients with acute coronary syndrome: a systemic review and meta-analysis. Mediators Inflamm. 2019;2019:2872607.
   PubMed Web of Science ®Google Scholar
• Dullaart RP, Tietge UJ, Kwakernaak AJ, Dikkeschei BD, Perton F, Tio RA. Alterations in plasma lecithin: cholesterolacyltransferase and myeloperoxidase in acute myocardial infarction: implications for cardiac outcome. Atherosclerosis. 2014;234(1):185–192.
   PubMed Web of Science ®Google Scholar
• Katakami N, Kaneto H, Matsuoka TA, et al. Accumulation of gene polymorphisms related to oxidative stress is associated with myocardial infarction in Japanese type 2 diabetic patients. Atherosclerosis. 2010;212(2):534–538.
   PubMed Web of Science ®Google Scholar
• Baker EN, Baker HM. Molecular structure, binding properties and dynamics of lactoferrin. Cell Mol Life Sci. 2005;62(22):2531–2539.
   PubMed Web of Science ®Google Scholar
• Baker EN, Baker HM. A structural framework for understanding the multifunctional character of lactoferrin. Biochimie. 2009;91(1):3–10.
   PubMed Web of Science ®Google Scholar
• Mayeur S, Spahis S, Pouliot Y, Levy E. Lactoferrin, a pleiotropic protein in health and disease. Antioxid Redox Signal. 2016;24(14):813–836.
   PubMed Web of Science ®Google Scholar
• Vengen IT, Dale AC, Wiseth R, Midthjell K, Videm V. Lactoferrin is a novel predictor of fatal ischemic heart disease in diabetes mellitus type 2: long-term follow-up of the HUNT 1 study. Atherosclerosis. 2010;212(2):614–620.
   PubMed Web of Science ®Google Scholar
• Aminian A, Boudjeltia KZ, Babar S, et al. Coronary stenting is associated with an acute increase in plasma myeloperoxidase in stable angina patients but not in patients with acute myocardial infarction. Eur J Intern Med. 2009;20(5):527–532.
   PubMed Web of Science ®Google Scholar
• Gaul DS, Stein S, Matter CM. Neutrophils in cardiovascular disease. Eur Heart J. 2017;38(22):1702–1704.
   PubMed Web of Science ®Google Scholar
• Ipek E, Yolcu M, Yildirim E, et al. A novel marker of inflammation: azurocidin in patients with st segment elevation myocardial infarction. Int J Mol Sci. 2018;19:12.
   Web of Science ®Google Scholar
• Edfeldt K, Agerberth B, Rottenberg ME, et al. Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(7):1551–1557.
   PubMed Web of Science ®Google Scholar
• Maneerat Y, Prasongsukarn K, Benjathummarak S, Dechkhajorn W, Chaisri U. Increased alpha-defensin expression is associated with risk of coronary heart disease: a feasible predictive inflammatory biomarker of coronary heart disease in hyperlipidemia patients. Lipids Health Dis. 2016;15:117.
   PubMed Web of Science ®Google Scholar
• Aghadavod E, Soleimani A, Amirani E, et al. Comparison between biomarkers of kidney injury, inflammation, and oxidative stress in patients with diabetic nephropathy and Type 2 diabetes mellitus. Iran J Kidney Dis. 2020;14(1):31–35.
   PubMed Web of Science ®Google Scholar
• Nandi SS, Katsurada K, Sharma NM, Anderson DR, Mahata SK, Patel KP. MMP9 inhibition increases autophagic flux in chronic heart failure. Am J Physiol Heart Circ Physiol. 2020;319(6):H1414–H1437.
   PubMed Web of Science ®Google Scholar
• Jiang XB, Yuan WS, Wang JS, Liu Z, Liu DH, Shi ZS. Matrix metalloproteinase-9 expression in carotid atherosclerotic plaque and contrast-enhanced MRI in a swine model. J Neurointerv Surg. 2014;6(1):24–28.
   PubMed Web of Science ®Google Scholar
• Papalambros E, Sigala F, Georgopoulos S, et al. Vascular endothelial growth factor and matrix metalloproteinase 9 expression in human carotid atherosclerotic plaques: relationship with plaque destabilization via neovascularization. Cerebrovasc Dis. 2004;18(2):160–165.
   PubMed Web of Science ®Google Scholar
• Chen F, Eriksson P, Hansson GK, et al. Expression of matrix metalloproteinase 9 and its regulators in the unstable coronary atherosclerotic plaque. Int J Mol Med. 2005;15(1):57–65.
   PubMed Web of Science ®Google Scholar
• Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene. 2000;19(21):2548–2556.
   PubMed Web of Science ®Google Scholar
• Chen Q, Lv J, Yang W, et al. Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis. Theranostics. 2019;9(22):6424–6442.
   PubMed Web of Science ®Google Scholar
• Samidurai A, Roh SK, Prakash M, et al. STAT3-miR-17/20 signalling axis plays a critical role in attenuating myocardial infarction following rapamycin treatment in diabetic mice. Cardiovasc Res. 2020;116(13):2103–2115.
   PubMed Web of Science ®Google Scholar
• Lin J, Wang T, Li Y, et al. N-acetylcysteine restores sevoflurane postconditioning cardioprotection against myocardial ischemia-reperfusion injury in diabetic rats. J Diabetes Res. 2016;2016:9213034.
   PubMed Web of Science ®Google Scholar
• Nourshargh S, Krombach F, Dejana E. The role of JAM-A and PECAM-1 in modulating leukocyte infiltration in inflamed and ischemic tissues. J Leukoc Biol. 2006;80(4):714–718.
   PubMed Web of Science ®Google Scholar
• Caligiuri G. CD31 as a Therapeutic target in atherosclerosis. Circ Res. 2020;126(9):1178–1189.
   PubMed Web of Science ®Google Scholar
• Newman PJ, Newman DK. Signal transduction pathways mediated by PECAM-1: new roles for an old molecule in platelet and vascular cell biology. Arterioscler Thromb Vasc Biol. 2003;23(6):953–964.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Gurbel PA. Effect of thrombolytic therapy on platelet expression and plasma concentration of PECAM-1 (CD31) in patients with acute myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19(1):153–158.
   PubMed Web of Science ®Google Scholar
• Reschner H, Milutinovic A, Petrovic D. The PECAM-1 gene polymorphism - a genetic marker of myocardial infarction. Cent Eur J Biol. 2009;4(4):515–520.
   Google Scholar